MOG and myeloid sarcoma: Are these atypical cases truly indicative of an atypical MOGAD, or are we potentially observing other conditions where the presence of MOG‐IgG is merely a secondary phenomenon or a result of cross‐immunogenicity, as described in MS [20]?